GSA Capital Partners’s Caris Life Sciences CAI Stock Holding History

GSA Capital Partners’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-15,235	Closed	-$411K	–	2246
2025 Q4	$411K	Buy	+15,235	New	+$429K	0.04%	951

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHWEPV

J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM

SSP

Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GSA Capital Partners's CAI Position: Q1 2026 in Review

GSA Capital Partners sold out of Caris Life Sciences (CAI) in Q1 2026, closing a stake of 15,235 shares — an estimated $411K sold.

GSA Capital Partners first reported a position in CAI in Q4 2025 and held it in 1 quarter. The position peaked at $411K in Q4 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

GSA Capital Partners reported no remaining Caris Life Sciences position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 15,235 Caris Life Sciences shares in Q1 2026, an estimated $411K.
GSA Capital Partners first reported a position in Caris Life Sciences in Q4 2025 and held it in 1 quarter.
GSA Capital Partners's Caris Life Sciences position peaked at $411K in Q4 2025.
202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.